Joint Q1 revenue beats analyst estimates on refranchising & portfolio optimization

Joint

07/05/2026 21:59

Overview

Chiropractic clinic franchisor's Q1 revenue rose 13%, beating analyst expectations

Net income increased 34% year-over-year; adjusted EBITDA rose 22%

Company repurchased $1.1 mln of shares during the quarter

Outlook

Company expects 2026 system-wide sales between $519 mln and $552 mln

Company sees 2026 system-wide comp sales in range of (3)% to 3%

Company expects 2026 consolidated adjusted EBITDA of $12.5 mln to $13.5 mln

Result Drivers

REFRANCHISING AND PORTFOLIO OPTIMIZATION - Co said revenue growth reflected early benefits from refranchising and portfolio optimization initiatives

LOWER REGIONAL DEVELOPER ROYALTIES - Cost of revenue declined primarily due to lower regional developer royalties

COST MANAGEMENT AND NEW INITIATIVES - Co cited disciplined cost management and new initiatives to strengthen patient engagement and support top-line growth

Company press release: ID:nGNXb14Hqp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$14.80 mln
$14.50 mln (4 Analysts)
Q1 EPS
$0.09
Q1 Net Income
$1.30 mln
Q1 Adjusted EBITDA
$3.50 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Joint Corp is $9.00, about 2.3% above its May 6 closing price of $8.80

The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)